Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 24

1.

Use of In Vitro Assays to Assess Immunogenicity Risk of Antibody-Based Biotherapeutics.

Joubert MK, Deshpande M, Yang J, Reynolds H, Bryson C, Fogg M, Baker MP, Herskovitz J, Goletz TJ, Zhou L, Moxness M, Flynn GC, Narhi LO, Jawa V.

PLoS One. 2016 Aug 5;11(8):e0159328. doi: 10.1371/journal.pone.0159328. eCollection 2016.

2.

Preclinical development of AMG 139, a human antibody specifically targeting IL-23.

Köck K, Pan WJ, Gow JM, Horner MJ, Gibbs JP, Colbert A, Goletz TJ, Newhall KJ, Rees WA, Sun Y, Zhang Y, O'Neill JC, Umble-Romero AN, Prokop SP, Krill CD, Som L, Buntich SA, Trimble MW, Tsuji WH, Towne JE.

Br J Pharmacol. 2015 Jan;172(1):159-72. doi: 10.1111/bph.12904. Epub 2014 Dec 15.

3.

Development of a human antibody tolerant mouse model to assess the immunogenicity risk due to aggregated biotherapeutics.

Bi V, Jawa V, Joubert MK, Kaliyaperumal A, Eakin C, Richmond K, Pan O, Sun J, Hokom M, Goletz TJ, Wypych J, Zhou L, Kerwin BA, Narhi LO, Arora T.

J Pharm Sci. 2013 Oct;102(10):3545-55. doi: 10.1002/jps.23663. Epub 2013 Aug 7.

PMID:
23925953
4.

A detailed examination of the antibody prevalence and characteristics of anti-ESA antibodies.

Barger TE, Wrona D, Goletz TJ, Mytych DT.

Nephrol Dial Transplant. 2012 Oct;27(10):3892-9. doi: 10.1093/ndt/gfs392.

PMID:
23114907
5.

The future of protein particle characterization and understanding its potential to diminish the immunogenicity of biopharmaceuticals: a shared perspective.

Bee JS, Goletz TJ, Ragheb JA.

J Pharm Sci. 2012 Oct;101(10):3580-5. doi: 10.1002/jps.23247. Epub 2012 Jun 26.

PMID:
22736570
6.

Highly aggregated antibody therapeutics can enhance the in vitro innate and late-stage T-cell immune responses.

Joubert MK, Hokom M, Eakin C, Zhou L, Deshpande M, Baker MP, Goletz TJ, Kerwin BA, Chirmule N, Narhi LO, Jawa V.

J Biol Chem. 2012 Jul 20;287(30):25266-79. doi: 10.1074/jbc.M111.330902. Epub 2012 May 14.

7.

Considerations for optimization and validation of an in vitro PBMC derived T cell assay for immunogenicity prediction of biotherapeutics.

Wullner D, Zhou L, Bramhall E, Kuck A, Goletz TJ, Swanson S, Chirmule N, Jawa V.

Clin Immunol. 2010 Oct;137(1):5-14. doi: 10.1016/j.clim.2010.06.018. Epub 2010 Aug 13.

PMID:
20708973
8.

Molecular alterations in pediatric sarcomas: potential targets for immunotherapy.

Goletz TJ, Mackall CL, Berzofsky JA, Helman LJ.

Sarcoma. 1998;2(2):77-87. doi: 10.1080/13577149878037.

9.

Intradermal vaccination of MUC1 transgenic mice with MUC1/IL-18 plasmid DNA suppresses experimental pulmonary metastases.

Shi FF, Gunn GR, Snyder LA, Goletz TJ.

Vaccine. 2007 Apr 30;25(17):3338-46. Epub 2007 Jan 22.

PMID:
17292519
10.

Engineering human IL-18 with increased bioactivity and bioavailability.

Swencki-Underwood B, Cunningham MR, Heavner GA, Blasie C, McCarthy SG, Dougherty T, Brigham-Burke M, Gunn GR, Goletz TJ, Snyder LA.

Cytokine. 2006 Apr;34(1-2):114-24.

PMID:
16750378
11.

A MUC1/IL-18 DNA vaccine induces anti-tumor immunity and increased survival in MUC1 transgenic mice.

Snyder LA, Goletz TJ, Gunn GR, Shi FF, Harris MC, Cochlin K, McCauley C, McCarthy SG, Branigan PJ, Knight DM.

Vaccine. 2006 Apr 12;24(16):3340-52. Epub 2006 Jan 19.

PMID:
16472547
12.

Induction of dendritic cell maturation by IL-18.

Li J, Mbow ML, Sun L, Li L, Yang G, Griswold DE, Schantz A, Shealy DJ, Goletz TJ, Wan J, Peritt D.

Cell Immunol. 2004 Feb;227(2):103-8.

PMID:
15135292
13.

Pilot trial of tumor-specific peptide vaccination and continuous infusion interleukin-2 in patients with recurrent Ewing sarcoma and alveolar rhabdomyosarcoma: an inter-institute NIH study.

Dagher R, Long LM, Read EJ, Leitman SF, Carter CS, Tsokos M, Goletz TJ, Avila N, Berzofsky JA, Helman LJ, Mackall CL.

Med Pediatr Oncol. 2002 Mar;38(3):158-64.

PMID:
11836714
14.

Antigenicity of fusion proteins from sarcoma-associated chromosomal translocations.

Worley BS, van den Broeke LT, Goletz TJ, Pendleton CD, Daschbach EM, Thomas EK, Marincola FM, Helman LJ, Berzofsky JA.

Cancer Res. 2001 Sep 15;61(18):6868-75.

15.

Regulatory CD4(+)CD25(+) T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer.

Woo EY, Chu CS, Goletz TJ, Schlienger K, Yeh H, Coukos G, Rubin SC, Kaiser LR, June CH.

Cancer Res. 2001 Jun 15;61(12):4766-72.

16.
17.

gp100/pmel 17 is a murine tumor rejection antigen: induction of "self"-reactive, tumoricidal T cells using high-affinity, altered peptide ligand.

Overwijk WW, Tsung A, Irvine KR, Parkhurst MR, Goletz TJ, Tsung K, Carroll MW, Liu C, Moss B, Rosenberg SA, Restifo NP.

J Exp Med. 1998 Jul 20;188(2):277-86.

18.
19.

Targeting HIV proteins to the major histocompatibility complex class I processing pathway with a novel gp120-anthrax toxin fusion protein.

Goletz TJ, Klimpel KR, Arora N, Leppla SH, Keith JM, Berzofsky JA.

Proc Natl Acad Sci U S A. 1997 Oct 28;94(22):12059-64.

20.

Delivery of antigens to the MHC class I pathway using bacterial toxins.

Goletz TJ, Klimpel KR, Leppla SH, Keith JM, Berzofsky JA.

Hum Immunol. 1997 May;54(2):129-36. Review.

PMID:
9297531
21.

Antigen expression by dendritic cells correlates with the therapeutic effectiveness of a model recombinant poxvirus tumor vaccine.

Bronte V, Carroll MW, Goletz TJ, Wang M, Overwijk WW, Marincola F, Rosenberg SA, Moss B, Restifo NP.

Proc Natl Acad Sci U S A. 1997 Apr 1;94(7):3183-8.

22.
23.

Molecular genetic approaches to the study of cellular senescence.

Goletz TJ, Smith JR, Pereira-Smith OM.

Cold Spring Harb Symp Quant Biol. 1994;59:59-66. Review.

PMID:
7587118
24.

Evidence for a genetic basis for the model system of cellular senescence.

Goletz TJ, Hensler PJ, Ning Y, Adami GR, Pereira-Smith OM.

J Am Geriatr Soc. 1993 Nov;41(11):1255-8. Review. No abstract available.

PMID:
8227901

Supplemental Content

Loading ...
Support Center